

France


Treatment at diagnosis by country

Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		France N=(1830)	World N=(52081)
Sex	Female, n (%)	826 (45.1)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	74.4 (11.3)	69.7 (11.5)
Age Group	<65, n (%)	337 (18.4)	15716 (30.2)
	65-74, n (%)	462 (25.2)	16956 (32.6)
	>=75, n (%)	1031 (56.3)	19409 (37.3)
BMI (kg/m ²)	mean (sd)	26.8 (5.1)	27.8 (5.7)
Pulse (bpm)	mean (sd)	89.9 (27.2)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	138.6 (21.3)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	79.6 (13.3)	79.7 (12.9)
Congestive heart failure	n (%)	199 (10.9)	10405 (20.0)
Coronary artery disease	n (%)	261 (14.3)	11251 (21.6)
Acute coronary syndrome	n (%)	174 (9.5)	4914 (9.5)
Carotid Occlusive Disease	n (%)	81 (4.5)	1546 (3.0)
Cirrhosis	n (%)	2 (0.1)	296 (0.6)

Baseline characteristics

		France N=(1830)	World N=(52081)
Diabetes	n (%)	320 (17.5)	11550 (22.2)
History of Bleeding	n (%)	79 (4.3)	1320 (2.5)
Hypercholesterolaemia	n (%)	688 (38.1)	20975 (41.6)
PE or DVT	n (%)	109 (6.0)	1356 (2.6)
Stroke/TIA	n (%)	399 (21.8)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	408 (28.8)	12547 (28.5)
	In the public sector, n (%)	1008 (71.2)	31431 (71.5)

Baseline characteristics

		France N=(1830)	World N=(52081)
CHADS2 Score	mean (sd)	2.1 (1.2)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	3.6 (1.6)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.6 (0.9)	1.4 (0.9)

Baseline characteristics

		France N=(1830)	World N=(52081)
Systemic Embolization	n (%)	7 (0.4)	336 (0.6)
Type of AF Diagnosed	New, n (%)	937 (51.2)	23366 (44.9)
	Paroxysmal, n (%)	553 (30.2)	14313 (27.5)
	Permanent, n (%)	159 (8.7)	6639 (12.7)
Care Setting Speciality at Diagnosis	Persistent, n (%)	181 (9.9)	7761 (14.9)
	Cardiology, n (%)	1337 (73.1)	34219 (65.7)
	Geriatrics, n (%)	9 (0.5)	202 (0.4)
	Internal Medicine, n (%)	71 (3.9)	9372 (18.0)
	Neurology, n (%)	318 (17.4)	876 (1.7)
	Primary Care/General Practice, n (%)	95 (5.2)	7410 (14.2)


Main reason anticoagulant not used for patients with $CHA_2DS_2-VASc \geq 2$.

	Cohort 1&2			
	France		World	
	(N=94)	(N=4137)	(N=4137)	(N=4137)
	n	%	n	%
Patients with $CHA_2DS_2-VASc \geq 2$ and no AC treatment at diagnosis				
Alcohol abuse			20	(0.5)
Already taking anti-platelet drugs for other medical condition	9	(9.6)	228	(5.5)
Patient refusal	3	(3.2)	336	(8.1)
Previous bleeding event	4	(4.3)	63	(1.5)
Taking medication contraindicated or cautioned for use with VKA or AC	1	(1.1)	19	(0.5)
Other	9	(9.6)	505	(12.2)
Unknown	8	(8.5)	889	(21.5)
Physician's choice	60	(63.8)	2077	(50.2)
Physician's choice - Bleeding risk	13	(13.8)	263	(6.4)
Physician's choice - Concern over patient compliance	5	(5.3)	182	(4.4)
Physician's choice - Guideline recommendation	2	(2.1)	105	(2.5)
Physician's choice - Fall risk	14	(14.9)	197	(4.8)
Physician's choice - Low risk of stroke	11	(11.7)	326	(7.9)
Physician's choice - Other	15	(16.0)	1004	(24.3)
Total	94	(100.0)	4137	(100.0)


Main reason anticoagulant not used for patients with CHA₂DS₂-VASc ≥ 2 .

	Cohort 3&4&5			
	France		World	
	(N=125)	(N=6117)	(N=6117)	(N=6117)
	n	%	n	%
Patients with CHA ₂ DS ₂ -VASc ≥ 2 and no AC treatment at diagnosis				
Alcohol abuse	1	(0.8)	32	(0.5)
Already taking anti-platelet drugs for other medical condition	12	(9.6)	422	(6.9)
Patient refusal	2	(1.6)	645	(10.5)
Previous bleeding event	22	(17.6)	151	(2.5)
Taking medication contraindicated or cautioned for use with VKA or AC	2	(1.6)	63	(1.0)
Other	18	(14.4)	1326	(21.7)
Unknown	14	(11.2)	1597	(26.1)
Physician's choice	54	(43.2)	1881	(30.8)
Physician's choice - Bleeding risk	29	(23.2)	611	(10.0)
Physician's choice - Concern over patient compliance	3	(2.4)	248	(4.1)
Physician's choice - Guideline recommendation	5	(4.0)	189	(3.1)
Physician's choice - Fall risk	10	(8.0)	205	(3.4)
Physician's choice - Low risk of stroke	7	(5.6)	628	(10.3)
Total	125	(100.0)	6117	(100.0)


Stroke risk profile: CHADS₂



Stroke risk profile: CHA₂DS₂ VASc



Stroke risk profile: HAS BLED




Treatment at diagnosis by CHA₂DS₂-VASc score - France

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
France	Unknown	18	15	6	6	10	2	57
	0	12	13	6	3	6	1	41
	1	46	37	8	28	27	2	148
	2	71	95	27	27	18	1	239
	3	147	131	36	54	32	3	403
	4	201	124	38	65	28	6	462
	5	119	62	23	26	16	4	250
	6-9	111	63	13	23	18	2	230


Treatment at diagnosis by CHA₂DS₂-VASc score - World

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



Treatment at diagnosis




Treatment at diagnosis by HAS BLED score - France

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
France	Unknown	235	153	57	80	61	7	593	593
	0	26	48	12	0	15	4	105	105
	1	189	188	47	20	32	7	483	483
	2	194	112	26	83	19	1	435	435
	3	66	30	15	38	22	2	173	173
	4-9	15	9	0	11	6	0	41	41


Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	France (N = 725) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	3706 (414)	157134 (8319)
	<2	866 (23.4)	50514 (32.1)
	2-3	2042 (55.1)	81056 (51.6)
	>3	798 (21.5)	25564 (16.3)
INR value	n (missing)	3706 (414)	157134 (8319)
	Mean (SD)	2.5 (0.9)	2.4 (0.9)
	Median (IQR)	2.4 (2.0 to 2.9)	2.3 (1.8 to 2.8)
	Min to Max	1.0 to 14.5	0.8 to 20.0
TTR, n(%)	n (missing)	311 (414)	11485 (8720)
	<65	154 (49.5)	6734 (58.6)
	>=65	157 (50.5)	4751 (41.4)
TTR	n (missing)	311 (414)	11485 (8720)
	Mean (SD)	60.5 (26.4)	55.2 (27.3)
	Median (IQR)	65.1 (44.0 to 80.3)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

Event rates during the first year of follow-up (rates per 100 person-years)

	France		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	111	6.86 (5.70 to 8.26)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	32	1.98 (1.40 to 2.80)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	48	2.97 (2.24 to 3.94)	771	1.61 (1.50 to 1.72)
Undetermined Cause	31	1.92 (1.35 to 2.72)	543	1.13 (1.04 to 1.23)
Stroke/SE	33	2.05 (1.46 to 2.89)	650	1.36 (1.26 to 1.47)
Major Bleeding	13	0.81 (0.47 to 1.39)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	10	0.62 (0.33 to 1.15)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	16	0.99 (0.61 to 1.62)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	France		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	10	31.3	262	33.2
Sudden or unwitnessed death	4	12.5	127	16.1
Myocardial infarction	0		89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	7	21.9	86	10.9
Non Cardiovascular causes				
Malignancy	12	25.0	233	30.2
Respiratory failure	12	25.0	142	18.4
Infection	2	4.2	81	10.5
Sepsis	3	6.3	74	9.6

Type of stroke during the first year of follow-up

	France		World	
	n	%	n	%
Stroke (not including systemic embolism)	27	1.48	585	1.12
Primary Ischemic	22	1.20	406	0.78
of which secondary hemorrhagic ischemic	1	0.05	22	0.04
Primary intracerebral hemorrhage			71	0.14
Intracerebral			44	0.08
Intraventricular			9	0.02
Subarachnoid			13	0.02
Undetermined	5	0.27	108	0.21

Severity of bleeding during the first year of follow-up

Outcome	France		World	
	n	%	n	%
Major Bleed	13	0.03	407	0.78
Non-Major Clinically Relevant	41	0.08	645	1.24
Minor	54	0.10	1167	2.24
Unknown	6	0.01	136	0.26